Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long‐Term Multicentre Real‐World Study
The safety and tolerability of omalizumab was confirmed. Notably, the wide variation in reported side effects across centres suggests that differences in awareness influence reporting. Hair loss was more prevalent than described before, warranting extra attention. Side effects were more often reported in patients whose characteristics suggest reduced effectiveness of omalizumab, possibly related to a negative association with omalizumab and suggesting increased disease burden. Availability of new therapies might increase the impact of side effects on treatment decisions, not only in omalizumab-refractory patients but potentially even among good responders.
Authors
- Juul M. P. A. van den Reek (ORCID: https://orcid.org/0000-0002-3642-2673)
- Carla Ritchie (ORCID: https://orcid.org/0000-0003-0538-8449)
- Andaç Salman (ORCID: https://orcid.org/0000-0002-6407-926X)
- Michael Rudenko (ORCID: https://orcid.org/0000-0002-6065-9451)
- Bahar Sevimli Dikicier (ORCID: https://orcid.org/0000-0002-1912-3946)
- Simon Francis Thomsen (ORCID: https://orcid.org/0000-0002-4838-300X)
- Stamatios Gregoriou (ORCID: https://orcid.org/0000-0002-7585-1032)
- Heike Röckmann (ORCID: https://orcid.org/0000-0002-8565-2619)
- Roberta Fachini Jardim Criado (ORCID: https://orcid.org/0000-0003-2482-3047)
- Nasser Mohammad Porras
- Esther Van der Wind
- Rabia Öztaş Kara (ORCID: https://orcid.org/0000-0003-1828-5844)
- Jennifer Astrup Sørensen (ORCID: https://orcid.org/0009-0001-4243-9535)
- Lea Kiefer (ORCID: https://orcid.org/0000-0003-2882-4784)
- Shunsuke Takahagi (ORCID: https://orcid.org/0000-0001-9951-1342)
- Andreas Kleinheinz (ORCID: https://orcid.org/0000-0002-0379-4403)
- Ana Maria Giménez‐Arnau (ORCID: https://orcid.org/0000-0001-5434-7753)
- Mehran Alizadeh Aghdam (ORCID: https://orcid.org/0000-0003-3584-9250)
- Yoshimi Matsuo
- André C. Knulst (ORCID: https://orcid.org/0000-0002-1056-3179)
- Martijn B. A. van Doorn (ORCID: https://orcid.org/0000-0003-1672-7899)
- Emek Kocatürk (ORCID: https://orcid.org/0000-0003-2801-0959)
- Marcus Maurer (ORCID: https://orcid.org/0000-0002-4121-481X)
- Reineke Soegiharto (ORCID: https://orcid.org/0000-0002-1942-2508)
- Fatih Demir (ORCID: https://orcid.org/0000-0002-8181-0739)
- Esmee van Lindonk
- Tatjana Bobylev
- Michihiro Hide
Institutions
- Sakarya University (TR)
- Hiroshima University (JP)
- University of Copenhagen (DK)
- Bahçeşehir University (TR)
- Radboud University Nijmegen (NL)
- Universitat Pompeu Fabra (ES)
- Utrecht University (NL)
- National and Kapodistrian University of Athens (GR)
- Bispebjerg Hospital (DK)
- Erasmus MC (NL)
- Hospital Italiano de Buenos Aires (AR)
- Radboud University Medical Center (NL)
- University Medical Center Utrecht (NL)
- Humboldt-Universität zu Berlin (DE)
- Hiroshima City Asa Citizens Hospital (JP)
- Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
- Centro Universitário Fundação Santo André (BR)
- Andreas Sygros Hospital (GR)
- Centre for Human Drug Research (NL)
- Elbe Kliniken Stade-Buxtehude (DE)
- Kent Hastanesi (TR)
- Acıbadem Adana Hospital (TR)
- Marmara University (TR)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Clinical & Experimental Allergy
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1111/cea.70067
- Citations
- 4
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 6.67
Funders
- Novartis Pharma